Vertex Offers Cystic Fibrosis Patients A Chance To Breathe Easier
This article was originally published in Pharmaceutical Approvals Monthly
While most attention has been on Vertex Pharmaceuticals' hepatitis C drug telaprevir, which is widely expected to gain FDA approval in May, the company has also been steadily progressing on its investigational cystic fibrosis agents, and it may have lined up another home run.
You may also be interested in...
Bolstered by a huge patient database, the Multiple Myeloma Research Consortium is helping to speed trials of new therapies, including some of the most talked about investigational drugs in the disease space, like carfilzomib and pomalidomide.
The outlook for cystic fibrosis drug development now is "a very different story than even five years ago," according to Cystic Fibrosis Foundation President Robert Beall.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.